Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | EBP | Q15125 | 1/20 | 0.62 |
| ▸ | GUSB | P08236 | 2/20 | 0.57 |
| ▸ | GBA1 | P04062 | 2/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.46 |
| ▸ | GLB1 | P16278 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19286100 | 1.00 | SIGMAR1 (0.62) | SIGMAR1EBPGUSBGBA1GNAI3 | |
| SCHEMBL17918911 | 0.91 | GLB1 (0.54) | SIGMAR1EBPGUSBGBA1GNAI3 | |
| SCHEMBL19119459 | 0.82 | EBP (0.67) | SIGMAR1EBPGUSBGBA1GNAI3 | |
| SCHEMBL15363076 | 0.82 | EBP (0.67) | SIGMAR1EBPGUSBGBA1GNAI3 | |
| SCHEMBL19606303 | 0.82 | EBP (0.67) | SIGMAR1EBPGUSBGBA1GNAI3 | |
| SCHEMBL15363010 | 0.82 | EBP (0.67) | SIGMAR1EBPGUSBGBA1GNAI3 | |
| SCHEMBL19939286 | 0.82 | SIGMAR1 (0.52) | SIGMAR1EBPGUSBGBA1GNAI3 | |
| SCHEMBL19578844 | 0.81 | SIGMAR1 (0.42) | SIGMAR1EBPGUSBGBA1GLB1 | |
| SCHEMBL15363044 | 0.79 | EBP (0.63) | SIGMAR1EBPGUSBGBA1GNAI3 | |
| SCHEMBL15362939 | 0.78 | EBP (0.62) | SIGMAR1EBPGUSBGBA1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | SIGMAR1 994/4885EBP 4483/4885GUSB 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.